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Background: EphA5 is a member of the Eph/ephrin family and plays a critical role in the regulation of carcinogenesis.
A significant reduction of EphA5 transcripts in high-grade prostate cancer tissue was shown using a transcriptomic
analysis, compared to the low-grade prostate cancer tissue. As less is known about the mechanism of EphA5
downregulation and the function of EphA5, here we investigated the expression and an epigenetic change of EphA5
in prostate cancer and determined if these findings were correlated with clinicopathologic characteristics of prostate
cancer.
Methods: Seven prostate cell lines (RWPE-1, LNCap, LNCap-LN3, CWR22rv-1, PC-3, PC-3M-LN4, and DU145), thirty-nine
BPH, twenty-two primary prostate carcinomas, twenty-three paired noncancerous and cancerous prostate tissues were
examined via qRT-PCR, methylation-specific PCR, bisulfite sequencing, immunohistochemistry and western blotting. The
role of EphA5 in prostate cancer cell migration and invasion was examined by wound healing and transwell assay.
Results: Downregulation or loss of EphA5 mRNA or protein expression was detected in 28 of 45 (62.2%) prostate
carcinomas, 2 of 39 (5.1%) hyperplasias, and all 6 prostate cancer cell lines. Methylation of the EphA5 promoter region
was present in 32 of 45 (71.1%) carcinoma samples, 3 of 39 (7.7%) hyperplasias, and the 6 prostate cancer cell lines.
Among 23 paired prostate carcinoma tissues, 16 tumor samples exhibited the hypermethylation of EphA5, and 15 of
these 16 specimens (93.8%) shown the downregulation of EphA5 expression than that of their respectively matched
noncancerous samples. Immunostaining analysis demonstrated that the EphA5 protein was absent or down-regulated
in 10 of 13 (76.9%) available carcinoma samples, and 8 of these 10 samples (80.0%) exhibited hypermethylation. The
frequency of EphA5 methylation was higher in cancer patients with an elevated Gleason score or T3-T4 staging.
Following the treatment of 6 prostate cancer cell lines with 5-aza-2′-deoxycytidine, the levels of EphA5 mRNA were
significantly increased. Prostate cancer cells invasion and migration were significantly suppressed by ectopic expression
of EphA5 in vitro.
Conclusion: Our study provides evidence that EphA5 is a potential target for epigenetic silencing in primary prostate
cancer and is a potentially valuable prognosis predictor and thereapeutic marker for prostate cancer.
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Prostate cancer (PCa) is the second most common male
malignancy and the sixth leading cause of cancer death
in men worldwide [1]. The disease burden is anticipated
to grow to 1.7 million new cases and 499,000 deaths by
2030 simply due to the expansion and aging of the glo-
bal population [2]. Understanding the molecular mecha-
nisms that regulate initiation and progression of PCa is
crucial for improving early diagnosis, developing rational
therapies, and predicting patient prognosis [3,4]. How-
ever, the current information that is available and that
can be applied in clinical practice is limited [3,4]. There-
fore, the identification of new molecular alterations
involved in the initiation and progression of this devas-
tating disease will likely lead to fewer cases of prostate
cancer and fewer deaths from the disease.
Eph receptors represent the largest family of receptor
tyrosine kinases (RTK) and include 14 human type 1
transmembrane protein members [5,6]. According to se-
quence homologies and ligand-binding affinities, Eph re-
ceptors and their ephrin ligands are divided into the
following two subgroups: class A and class B [6]. Eph re-
ceptors share a common protein structure, including an
extracellular domain (consisting of a globular domain, a
cysteine-rich domain, and two fibronectin type III re-
peats domains), a transmembrane portion and an intra-
cellular domain (consisting of a tyrosine kinase domain,
a sterile alpha motif [SAM] and a PDZ binding domain)
[7]. The aberrant methylation of CpG island promoter
regions of Eph receptor genes is frequently observed
during the development of many types of cancers, par-
ticularly prostate cancer [8-15].
EphA5, located on chromosome 4q13.1, is a member
of the Eph receptor family. In common with other mem-
bers of the Eph subgroup, EphA5 plays a critical role in
the regulation of carcinogenesis and cancer progression
[14,15]. Interestingly, a recent transcriptomic analysis re-
vealed that the EphA5 gene is downregulated in radical
prostatectomy patients with high grade PCa with a Gleason
score of 8,suggesting that EphA5 plays a crucial role in
prostate cancer progression [16]. However, the function of
EphA5 and its clinical significance in prostate cancer has
never been addressed. Here, we demonstrated that EphA5
is frequently downregulated in patients with prostate can-
cer. Furthermore, we explored the mechanism responsible
for the downregulation of EphA5 and investigated its bio-
logical function and the association between EphA5 alter-
ations and clinical characteristics of these patients.
Methods
Cell culture
The RWPE-1, PC-3 and Du145 cell lines were purchased
from the Institute of Biochemistry and Cell Biology,
Chinese Academy of Sciences (Shanghai, China). TheLNCap, LNCap-LN3, PC-3M-LN4, and CWR22rv-1 cell
lines were kindly provided by Dr. Zhang (Biomedical Re-
search Institute, Shenzhen PKU-HKUST Medical Center,
Shenzhen, China). All of the cell lines were cultured in
RPMI 1640 medium (HyClone, Logan, UT) containing
10% fetal bovine serum, penicillin (100 U/ml) and strep-
tomycin (100 U/ml) in a 5% CO2 atmosphere at 37°C.
Cells were seeded at a density of 5 × 104 cells per square
centimeter in a 6-well plate. After 36 hours of incubation,
fresh culture medium with or without demethylating agent
5-aza-2′-deoxycytidine was added (5 μmol/L, Sigma-
Aldrich, USA); cells were then incubated for an additional
48 hours.
Patients and tissues
All tissue specimens were obtained between March
2013 and December 2013 at the Urology Department of
Huashan Hospital (Shanghai, China). Benign prostate
hyperplasia (BPH) samples (39) and some of the prostate
carcinoma (22) samples were collected from patients
undergoing prostate needle biopsies, and 23 paired non-
cancerous and tumor tissue samples were obtained from
patients following radical prostatectomy. Paired normal
specimen was obtained from an area that was at least 1cm
away from any cancerous tissue and did not contain either
cancer cells or premalignant tissue morphologically by
histological examination of sequential sections. All of the
cancer samples were histologically confirmed to contain
greater than 80% tumor cells. Staging was assessed after
pathological examination of formalin-fixed specimens ac-
cording to the 1997 TNM classification system. Written
consents were obtained from all subjects and the study
protocol was approved by the Ethics Committee of Hua-
shan Hospital. Clinical and biological data from the pa-
tients are listed in Table 1.
Gene expression analysis by real-time PCR
Total RNA was extracted from cells and tissues using the
AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Germany),
and samples were reverse transcribed using the Prim-
ScriptTM RT Reagent Kit (TaKaRa, China) as described in
the manufacturer’s protocol. Real-time PCR to determine
EphA5 and GAPDH mRNA levels was performed using
the QuantiFast Probe PCR Kit (Qiagen, Germany) accord-
ing to the manufacturer’s instructions; all analyses were
conducted using the ABI Prism 7500 sequence detection
system (Applied Biosystems, CA). The relative quantifica-
tion of EphA5 mRNA levels was performed using the
comparative Ct method (2-△△Ct method) with GAPDH as
the reference gene. Increases or decreases in mRNA levels
of at least two fold were considered to be significant. The
primer sequences were as follows: EphA5 forward, 5’-
TCTGTGGTACGACACTTGGC-3’; EphA5 reverse, 5’-
CTTGCACATGCATTTCCCGA-3’; GAPDH forward,
Table 1 Patient clinical and histological characteristics
Prostate cancer (%) BPH (%)
Case, n 45 39










<4.0 2 (4.4) 4 (10.3)
4.0–10.0 7 (15.6) 21 (53.8)
>10.0 36 (80.0) 14 (35.9)
Prostate volume (ml)
<30 14 (31.1) 8 (20.5)
30–50 17 (37.8) 12 (30.8)
>50 14 (31.1) 19 (48.7)
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5’-AGTGATGGCATGGACTGTGG-3’.
Methylation-specific PCR
Genomic DNA was isolated from cells and tissues using
the AllPrep DNA/RNA/Protein Mini Kit (Qiagen, German)
and modified using the EZ DNA Methylation-Gold Kit
(ZYMO Research Co, Orange, CA) according to the man-
ufacturer’s instructions. To identify aberrant methylation
of the EphA5 gene, the modified DNA was amplified using
primers specific for the methylated sequence (MSP, forward
primer: 5′-ATTGAGTCGTTCGGGATAGC-3′ and re-
verse primer: 5′-GTCGAAATACAAAATAACAACCGA-
3′) and primers specific for the unmethylated sequence
(USP, forward primer: 5′-GATTGAGTTGTTTGGGAT
AGTGG-3′ and reverse primer: 5′-CCATCAAAATACA
AAATAACAACCA-3′) using TaKaRa HotStarTaq DNA
polymerase [15]. Amplicons were separated on 3% agarose
gels and visualized under ultraviolet illumination.
Bisulfite genomic sequencing
The sodium bisulfite-modified DNA was amplified via
PCR using the following primers: Bis-EphA5-F (5′-
TGGTTTTTATATTTGGAGGAGT-3′) and Bis-EphA5-R
(5′-AAAACCTAAACTCCCAAACC-3′) [15]. PCR prod-
ucts were purified using the QIAquick PCR Purification
Kit (Qiagen; Valencia, CA), subcloned into the pMD19-T
vector (TaKaRa), transformed into E. coli (DH5-alpha) and
grown on LB agar plates containing kanamycin with
X-gal/IPTG for blue/white selection. To detect themethylation status of the EphA5 promoter, six isolated
colonies from each plate were picked, sequenced and an-
alyzed using an ABI 3730 DNA Sequencer (Applied
Biosystems).
Western blot analysis
Total protein was extracted from prostate tissue and cell
lines using radioimmunoprecipitation assay (RIPA) buf-
fer, and protein concentrations were determined using
the BCA Protein Reagent Kit (Beyotime, China) accord-
ing to the manufacturer's instructions. Proteins (100 μg)
were separated via SDS-PAGE on an 8% gel, transferred
to a polyvinylidene fluoride membrane, and incubated
with the following antibodies: rabbit anti-EphA5 (1:500,
Abcam, CA) and mouse anti-beta-actin (1:1000, Santa
Cruz, CA) overnight at 4°C. After washing, the mem-
branes were incubated with HRP-conjugated goat poly-
clonal secondary antibodies to mouse IgG and rabbit
IgG (1:5000, Abcam, CA) for 2 h and visualized with
enhanced chemiluminescent substrate (Millipore, CA).
Then, immunoreactive bands were quantified using the
LAS-3000 system (Fuji Film, Japan).
Immunohistochemistry (IHC) and Imaging
Tissues were fixed in 4% formalin, embedded in paraffin
and sectioned at a thickness of 4 microns. Sections were
deparaffinized in several xylene washes and then rehy-
drated in graded alcohols. The sections were perme-
abilized in citrate buffer (pH 6.0, Maixin) for 10 min and
then incubated with normal goat serum for 1 h. Next,
the sections were incubated with rabbit anti-EphA5
polyclonal antibody (dilution 1:1000, Abcam, CA) for
1 h at 37°C and then stained using an HRP-conjugated
secondary antibody (Dako, UK) for 1 h at room
temperature. Finally, the sections were incubated and
stained with DAB substrate and hematoxylin, scanned
with an Olympus BX53 microscope and photographed
using the Cellsens Entry software (Olympus). EphA5 ex-
pression was classified as negative if less than 5% of the
tumor cells were positive for EphA5 staining and classi-
fied as positive if more than 5% of the tumor cells were
positive for EphA5 staining.
Scratch migration assay and Invasion assay
For evaluation the EphA5 function,we obtained the Du145
derivative cell lines that stably overexpressed EphA5 via
transfection of pCMV6-AC-GFP-EphA5 plasmid (Cat No.
RG213206, Origene, CA) according to the manufacturer’s
protocol. Du145 cell transfected with pCMV6-AC-GFP
empty plasmid (Cat No. PS100010, Origene, CA) empty
vector were used as the control.
For scratch migration assay, cells were cultured in 24-
well plates until confluence. The monolayer was scratched
with a sterile 200 μl pipette tip to create a denuded area of
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photographed before and 24 hours after wounding.
For the Matrigel invasion assay, 1 × 105 cells were
seeded into the upper compartment of the insert with
Matrigel (BD Biosciences, Woburn, Mass) in serum-free
growth medium. Then, the upper chamber were placed
into 24-well culture dishes containing 600 μl of complete
growth medium. After 48h of incubation at 37°C, cells in
the upper chamber were subsequently removed with cot-
ton swabs and then stained with a solution containing
0.1% crystal violet and 4% formaldehyde. The number of
cells that fixed on the bottom membrane of the inserts
was counted.
Statistics
A two-tailed Student's t-test was used to compare vari-
ous groups to assess statistical significance. The differ-
ences in gene expression levels between prostate cancer
samples and noncancerous prostate tissue specimens
were analyzed using a chi-squared test. All statistical
analyses were performed using the SPSS 11.0 software.
P < 0.05 was considered to be statistically significant.
Results
Down-regulation of EphA5 in prostate cancer
To explore the potential role of EphA5 in prostate car-
cinogenesis, we first analyzed its expression by real-time
PCR in a panel of human nonmalignant (RWPE-1) and
prostate cancer (LNCaP, LNCaP-LN3, PC-3, PC-3M-
LN4, CWR22rv-1, and DU145) cell lines. EphA5 mRNA
expression was significantly decreased in all six prostate
cancer cell lines compared to the nonmalignant RWPE-
1 cells (Figure 1A). In addition, we also observed that
EphA5 gene expression was decreased consistently and
significantly in both lymph node derivative cell lines
compared to their parental prostate cancer cells LNCaPFigure 1 qRT-PCR and Western blot analysis of EphA5 expression in p
qRT-PCR in 7 prostate cell lines. GAPDH was amplified as an internal control. B
prostate cell lines. β-Actin (43 kDa band) was used as a control for equal load
shown as mean ± SD (n = 3). *P < 0.05, vs. the RWPE-1 cell line; **P < 0.05, vs. tand PC-3 (Figure 1A). We further investigated the
EphA5 protein levels by Western blotting analyses in
these cell lines. The protein levels were consistent with
the respective mRNA levels for the various cell lines
(Figure 1B).
To determine whether epigenetic silencing of the
EphA5 gene also occurs in primary prostate tumors,
EphA5 expression was analyzed by real-time PCR in 39
BPH tissues, 22 primary prostate tumor tissues and 23
paired noncancerous and tumor tissues. EphA5 mRNA
expression was downregulated in 28 of 45 (62.2%) pros-
tate cancer samples and in 2 of 39 (5.1%) BPH samples
(Table 2). Among the 23 paired prostate carcinoma
specimens, 15 (65.2%) tumor tissues exhibited the down-
regulation of EphA5 when compared with their respect-
ively matched noncancerous tissues (Additional file 1:
Table S1).
To further validate the expression of EphA5 in human
PCa tissue, we also analysed 4 BPH tissues, 5 primary
prostate tumors tissues and 4 paired normal tissues in
our study by Western blotting assay. Similar to the re-
sults of qRT–PCR in the corresponding tissues, EphA5
protein level in prostate tumour samples was signifi-
cantly lower than that of matched adjacent normal tis-
sues or BPH tissues (Figure 2).
Methylation status of EphA5 in prostate cancer
To determine the potential mechanism of EphA5 down-
regulation in prostate cancer, we analyzed the EphA5 gene
5′ regulatory region. We found a CpG island encompass-
ing the transcription start site (TSS) of EphA5. Then,
methylation-specific PCR (MSP-PCR) was performed to
examine the methylation status of each of the cell
lines. Methylated DNA was detected in all six prostate
cancer cell lines, whereas the hypermethylation of
EphA5 gene was not detected in nonmalignant RWPE-1rostate cell lines. A, EphA5 mRNA expression was analyzed by
, Western blot analysis of EphA5 protein (114 kDa band) expression in 7
ing of cell lysates. Representative results of triplicate experiments are
he LNCaP cell line, ***P < 0.05, vs. the PC-3 cell line.
Table 2 Correlation of EphA5 methylation and mRNA
expression with clinical and histological parameters in
PCa patients
Methylation p-value1 mRNA expression p-value1
Present Absent Normal Reduced
Age (years)
≤70 18 7 0.883 8 17 0.371
>70 14 6 9 11
PSA (ng/ml)
≤10 6 3 0.742 2 7 0.537
>10 26 10 15 21
Stage (TNM)
T1-T2 6 7 0.019 7 6 0.156
T3-T4 26 6 10 22
Gleason score
6-7 12 10 0.016 12 10 0.023
8-10 20 3 5 18
Prostate volume (ml)
≤50 24 7 0.165 11 20 0.637
>50 8 6 6 8
Normal: 0.5 ≤ 2-△△Ct ≤2; Reduced: 2-△△Ct < 0.5; 1χ2 (2-tailed).
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methylated sequences were observed in the PC-3 cell line,
indicating partial methylation.
To determine whether EphA5 hypermethylation also
occurs in primary prostate tumors, the methylation sta-
tus of EphA5 was determined by MSP-PCR in 39 BPH
tissues, 22 primary prostate tumor tissues and 23 paired
noncancerous and tumor tissues. The frequency of
EphA5 promoter methylation was significantly higher inFigure 2 Western blotting analysis of EphA5 protein expression in cli
representative resected fresh prostate cancer tissues and matched non-tum
β-actin expression (43 kDa band). Expression was further normalized to the
B, EphA5 protein levels (114 kDa band) in representative fresh prostate can
analyzed by western blotting and normalized to β-actin (43 kDa band). Pro
the first benign prostate hyperplasia specimen. Representative results from
the respective noncancerous tissue and BPH. N = non-tumor tissue; T = tumprostate cancer samples (32 of 45, 71.1%) than in BPH
tissue samples (5 of 39, 12.8%; p < 0.01) and paired non-
cancerous tissues (2 of 23, 8.7%; p < 0.01). Of these 32
methylated prostate cancer samples, EphA5 expression
was markedly downregulated in 25 samples. The correl-
ation between EphA5 expression and hypermethylation
of the CpG island was significant (p = 0.001). Among the
23 paired prostate carcinoma specimens, the hypermethy-
lation of EphA5 was detected in 69.6% (16/23) prostate
carcinoma tissues. Of these 16 prostate cancer samples, 15
(93.8%) exhibited the downregulation of EphA5 expression
than that of their respectively matched noncancerous tis-
sues, implying that the hypermethylation of EphA5 was
significantly correlated with the downregulation of EphA5
(p < 0.01) (Additional file 1: Table S1). The unmethylated
form of EphA5, which was present in all samples, is likely
due to the inherent contamination with normal (nonma-
lignant) cells or partial methylation. Representative results
from MSP–PCR analyses in prostate tissue are shown in
Figure 4A.
To further verify the MSP-PCR results, we subjected
all of the cell lines and randomly selected tissue samples
to bisulfite sequencing. We analyzed a 406 bp segment
of the EphA5 gene 5′ regulatory region (−103 to +303 bp;
TSS, +1 bp), which includes 38 CpG sites and spans the
core promoter, exon 1, and part of intron 1 (Figure 3B).
Similar to the MSP-PCR results, the CpG sites were
hypermethylated in all six tumor cell lines (LNCaP,
LNCap-LN3, PC-3, PC-3M-LN4, CWR22rv-1, and DU145),
and in some of the prostate carcinoma and hyperplasia
specimens (Figures 3C and 4B). Representative exam-
ples displaying frequent, localized methylation at the
CpG island for all six prostate tumor cell lines and a
prostate carcinoma sample (T24) are shown in Figure 3D.nical prostate specimens. A, EphA5 protein (114 kDa band) levels in
or tissues were analyzed by western blotting and normalized to
expression level observed in the first noncancerous specimen.
cer tissues (collected via biopsy) and benign prostate hyperplasias were
tein levels were further normalized to the expression level observed in
triplicate experiments are shown as mean ± SD (n = 3). *P < 0.05, vs.
or tissue; BPH = benign prostate hyperplasia.
Figure 3 Methylation status of the EphA5 gene promoter in prostate cell lines. A, EphA5 methylation status was determined by MSP-PCR
analysis. All prostate cancer cell lines exhibited complete methylation of the EphA5 gene. Unmethylated EphA5 alleles were detected in RWPE-1 and
PC-3 cell lines. Lanes labeled “M” and “U” denote products amplified with primers recognizing methylated and unmethylated sequences, respectively.
B, Schematic depiction of the EphA5 promoter-associated CpG island, which spans the region from -103 to +303 with respect to the TSS (+1). The
bisulfite sequencing PCR primers are shown in light blue and bold type. The MSP = PCR primers are highlighted in khaki, italicized, and underlined.
There are 38 CpG sites in this region; the CpG sites are numbered in red and bold type. C, Methylation patterns of individual EphA5 promoter clones
from prostate cell lines that were sequenced using bisulfite methods. Six clones from each sample were bisulfite sequenced to obtain a representative
sampling of methylation patterns; CpG dinucleotides are represented by squares (■, methylated cytokines; □, unmethylated cytosines). Cell-line names
and the percentage of methylation for the corresponding cell line are indicated on the left and right sides, respectively. D, Representative chromatograms
of CpG sites 14 to 18 obtained from bisulfite sequencing of the EphA5 fragment. Arrows indicate positions of CpG dinucleotides.
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malignant cell line and a noncancerous prostate sample
(N1) are shown in Figure 4C.
Immunohistochemical expression of EphA5
To further verify the expression of EphA5 in human
prostate tumors, we examined its expression via immu-
nohistochemistry in 13 paired prostate carcinomas and
noncancerous tissues. Strong immunostaining of the
EphA5 protein was observed in the cytoplasm of all 13
paired noncancerous tissues. Among the 13 prostate car-
cinoma specimens, 10 (76.9%) exhibited undetectable or
weak immunostaining. Of these 10 tumor tissues, hyper-
methylation was present in 8 samples (80.0%). There
was a strongly negative correlation between promoter
hypermethylation of the EphA5 gene and EphA5 protein
expression (p = 0.012). Representative examples displayingpositive EphA5 protein immunostaining in a noncancer-
ous prostate sample, weak EphA5 protein immunostaining
in a low-grade prostate cancer specimen (Gleason score =
7) and negative EphA5 protein immunostaining in a high-
grade prostate carcinoma sample (Gleason score = 9) are
shown in Figure 5.
Restoration of EphA5 gene expression by treatment with
5-aza-2′-deoxycytidine
To determine whether the inhibition of cytosine methy-
lation could induce EphA5 mRNA expression in cell
lines with hypermethylated CpG islands, we treated all
of the cell lines with the cytosine methylation inhibitor
5-aza-2′-deoxycytidine (5 μmol/L, 48 h). Compared with
untreated cells, the EphA5 mRNA level was significantly
increased in LNCaP (36.7 ± 5.9-fold, p = 0.0021), LNCaP-
LN3 (40.6 ± 4.4-fold, p = 0.0001), PC-3 (12.7 ± 3.7-fold,
Figure 4 Methylation status of the EphA5 gene promoter in prostate tissue. A, EphA5 methylation status was determined by MSP-PCR. All
of the prostate cancer tissues exhibit complete methylation of the EphA5 gene. The unmethylated alleles were detected in adjacent noncancerous
(top) and BPH (bottom) tissues. Lanes labeled “M” and “U” denote products amplified by primers recognizing methylated and unmethylated sequences,
respectively. B, Methylation patterns of individual EphA5 promoter clones from prostate tissue that were bisulfite sequenced are shown. Six clones from
each sample were bisulfite sequenced to obtain a representative sampling of methylation patterns; CpG dinucleotides are represented by squares (■,
methylated cytokines; □, unmethylated cytosines). Sample names and the methylation percentage of the corresponding tissue are indicated on the left
and right sides, respectively. C, Representative examples of an unmethylated EphA5 CpG island in sample N1 (top) and a highly methylated CpG island
in sample T24 are shown, as determined by bisulfite sequencing analysis. Arrows indicate positions of CpG dinucleotides.
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CWR22rv-1 (39.1 ± 4.8-fold, p = 0.0063), and DU145
(42.9 ± 9.8-fold, p = 0.0039) cells. However, there was
no significant enhancement of EphA5 mRNA levels in
the RWPE-1 nonmalignant cells following 5-aza-2′-
deoxycytidine treatment for 48 h (Figure 6). These re-
sults suggest that DNA hypermethylation is involved
in EphA5 gene silencing in prostate cancer cell lines.
Correlation between the mRNA expression and
methylation of EphA5 and clinicopathologic features
We analyzed various patient clinicopathologic parameters
in relation to the downregulation and methylation of
EphA5. EphA5 expression differences were not correlatedFigure 5 Representatively immunostaining analysis of EphA5 in prost
noncancerous prostate tissue sample N8. B. Weak cytoplasmic expression of E
C. Complete loss of EphA5 expression in the prostate carcinoma sample T8 (Gwith median age (p = 0.371), TNM stage (p = 0.156), PSA
serum concentration (p = 0.537) or prostate volume (p =
0.637). However, the low Gleason score group (Gleason
score: 6-7) had significantly higher expression of EphA5
than the high Gleason score group (Gleason score: 8-10)
(45.5% vs. 78.3%; p = 0.023). Significant correlations were
observed between the frequency of EphA5 methylation
and TNM staging (p = 0.019) and Gleason score (p =
0.016). However, no significant difference between the
Gleason score 7 (3 + 4) group and the Gleason score
7 (4 + 3) group was observed about the expression of
EphA5 and the hypermethylation of EphA5 (data not
shown). No correlation between the occurrence of EphA5
hypermethylation and prostate-specific antigen (PSA) levelsate tissue. A. Strong cytoplasmic expression of EphA5 in the adjacent
phA5 in the prostate carcinoma tissue sample T6 (Gleason score = 3 + 4).
leason score = 4 + 5) (scale bar = 50 μm).
Figure 6 EphA5 mRNA expression analysis by qRT-PCR in 7
prostate cells lines following 5-aza-2'-deoxycytidine (5 μmol/l)
treatment for 0 and 48 hr. EphA5 gene expression levels for cell
lines treated with 5-aza-2'-deoxycytidine are shown as the relative
fold change compared to untreated cells (0 hours, defined as 1.0).
Representative results from experiments conducted in triplicate are
shown as mean ± SD. *Denotes statistical significance at P < 0.05
compared to values at 0 hours.
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observed (Table 2).
Overexpression of EphA5 inhibits prostate cancer cell
invasion and migration
To assess the effect of EphA5 expression on invasion
and migration, we transiently infected Du145 cells lack-
ing expression of EphA5 with plasmid expressing
pCMV6-AC-GFP or pCMV6-AC-GFP-EphA5 and gen-
erated stably transfected cells using G418 selection.
Western blotting analysis demonstrated that EphA5 was
over-expressed in DU145 cells transfected with pCMV6-
AC-GFP-EphA5 (Figure 7A). The wound healing assay
demonstrated that the wound-closure rate of pCMV6-
AC-GFP-EphA5 cells decreased by 33.7% (p <0.05) when
compared with control pCMV6-AC-GFP cell (Figure 7C).
The transwell assay showed that the number of invasive
cells in pCMV6-AC-GFP-EphA5 cells decreased by
38.1% (p <0.05) when compared with control pCMV6-
AC-GFP cell (Figure 7B). These data implied that EphA5
expression inhibited cell migration and invasion in vitro.
Discussion
In this study, we systematically evaluated the expression
profile and methylation status as well as its clinical rele-
vance of the EphA5 gene in prostate cell lines, benign
prostatic hyperplasia, primary human prostate tumors,
and paired noncancerous tissues. The EphA5 gene was
frequently silenced by an epigenetic alteration, namely
DNA methylation in prostate cancer cell lines and tis-
sues. To the best of our knowledge, the present study is
the first to report the relationship between EphA5expression level and its methylation status in prostate
cancer.
Numerous reports have demonstrated that, similarly
to the other members of the Eph family, EphA5 not only
is involved in a variety of developmental processes
[14,17,18], but also plays important roles in carcinogen-
esis and the tumor progression of many cancers
[10,15,19-23]. A recent report revealed that EphA5 ex-
pression was decreased in low-grade glioma tumor tis-
sues and was further reduced in high-grade glioma
tumor tissues compared to normal control brain tissues,
which suggested a novel role of EphA5 as a tumor sup-
pressor [19]. Moreover, the downregulation of EphA5
expression was also observed in other advanced tumors,
including colorectal cancer, acute lymphocytic leukemia,
and breast cancer [10,15,20,21]. Consistent with previous
studies, the downregulation of EphA5 expression was
also observed in 28 of 45 (62.2%) prostate cancer tissues
with various histological stages and in all 6 PCa cell
lines. The downregulation of EphA5 was also associated
with increased Gleason score in prostate cancer. An-
other fact that supports the importance of EphA5 in
prostate cancer metastasis is that EphA5 transcript and
protein levels were reduced consistently and significantly
in both of the lymph node-derived cell lines compared
with their parental prostate cancer cells (LNCaP and PC-
3). The evidence suggests a potentially suppressive role of
EphA5 transcripts in prostate carcinoma progression.
DNA methylation/demethylation at promoter cytosine
residues within conserved CpG islands is a powerful epi-
genetic modification that regulates gene transcription,
and aberrant methylation can lead to gene silencing of
critical genes and has been a well-documented phe-
nomenon in many malignancies, particularly in prostate
carcinoma [8-11,20,24]. Recently several groups demon-
strated EphA5 promoter methylation in breast cancer,
colorectal cancer and acute lymphoblastic leukemia
[10,15,20], implying that the hypermethylation of EphA5
paly an important role in cancer progress. Similarly to pre-
vious studies, EphA5 gene hypermethylation was also de-
tected in all 6 PCa cell lines and in 71.1% of tumor
samples, whereas only 12.8% of benign prostatic hyperpla-
sia and 8.7% of paired noncancerous tissues exhibited
hypermethylation of the EphA5 gene within the same
CpG islands as the study on breast tumor. These findings
suggest that EphA5 hypermethylation occurred specifically
during prostate tumorigenesis and indicate that EphA5
could be used as a potential marker to distinguish malig-
nant prostate tissue from nonmalignant tissue. Moreover,
the significant associations of EphA5 methylation with
higher clinicopathologic TNM staging and Gleason score
support the important role of EphA5 in cancer progres-
sion. TNM staging and Gleason score are two practical
parameters that are often used to estimate prostate cancer
Figure 7 EphA5 overexpression inhibited the migration and invasiveness of Du145 cells. A. Western blot analysis of EphA5 protein (114
kDa band) expression in DU145 cells after transfection with pCMV6-GFP-EphA5. B. Cell migration activity determined with the wound healing
assay. C. Cell invasion activity determined with the Matrigel invasion assay (×100). All experiments were performed in triplicate. Data are shown as
the mean ± SD. *P < 0.05 vs. pCMV6-AC-GFP group.
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as a marker for biological aggressiveness and as a valuable
prognostic predictor of prostate cancer.
Additionally, to elucidate the mechanisms leading to
the downregulation of EphA5 expression in prostate
cancer, we determined the relationship between tran-
script expression level and the methylation status of
EphA5 in prostate cancer cell lines and tissues. A signifi-
cant correlation was observed between the downregula-
tion of EphA5 expression and EphA5 methylation in
prostate cancer. EphA5 expression was downregulated
in all 6 PCa cell lines harboring the methyaltion. Fur-
thermore, the downregulation of EphA5 expression
could be reversed in all 6 PCa cell lines by treating cells
with the DNA demethylating agent 5-aza-2′-deoxycyti-
dine, implying that hypermethylation was an important
reason for promoting the downregulation of EphA5
expression in prostate cancer. Our findings also provided
a good explanation for a previous study that EphA5
mRNA levels were decreased in high-grade (Gleasonscore = 8) PCa tissues compared to low-grade (Gleason
score = 6) PCa tissues [16].
To further evaluate whether EphA5 played a functional
role in the PCa, we assessed the changes of biological
characteristics in PCa cell line (Du145) after ectopic ex-
pression of EphA5. We found that EphA5 overexpression
significantly decreased Du145 cell migratory and invasive
capabilitie in vitro, suggestting that EphA5 may potentially
suppress prostate cancer metastasis.
Paradoxically, recent studies [22,23] have demonstrated
that the EphA5 gene was upregulated in high-grade hepa-
tocellular carcinoma. The findings described above
prompted us to ask whether EphA5 receptor can act in a
bimodal manner. Similar questions have already been ad-
dressed for other Eph receptors, such as EphA2, EphA7,
and EphB4 [9,25-28]. These findings could also be reflect-
ive of Eph/ephrin functions that are influenced by tissue
type, oncogenic context, or ligand-independent versus
ligand-dependent signaling. Therefore, the detailed role of
EphA5 in prostate cancer warrant further investigation.
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In summary, we have established that loss of EphA5 ex-
pression in prostate cancer may be due to methylation
of CpG sites within the EphA5 promoter. Our data indi-
cate that EphA5 is a potential prognostic biomarker and
a useful molecular therapeutic target to attenuate pros-
tate cancer progression.
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